In particular, the treatment with tumor-associated ExVs inhibited maturation and migration of DCs, promoted immune suppression of DCs, decreased CD4+IFN-γ+Th1 cell differentiation and increased the presence of Tregs. This evidence concerns the gene CD4 and neoplasm.